Tranexamic Acid in Nasal Mohs Reconstruction

Description

This study will be a prospective randomized control trial to evaluate the effects of subcutaneously administered TXA among patients undergoing nasal Mohs reconstruction with local flaps at VUMC.

Conditions

Postoperative Bleeding, Skin Cancer Face

Talk to us

Study Overview

On this page

Study Details

Study overview

This study will be a prospective randomized control trial to evaluate the effects of subcutaneously administered TXA among patients undergoing nasal Mohs reconstruction with local flaps at VUMC.

Subcutaneous Tranexamic Acid in Nasal Mohs Local Flap Reconstruction: Perioperative Bleeding, Edema, and Ecchymosis

Tranexamic Acid in Nasal Mohs Reconstruction

Condition
Postoperative Bleeding
Intervention / Treatment

-

Contacts and Locations

Nashville

Vanderbilt University Medical Center, Nashville, Tennessee, United States, 37232

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Adults at least 18 years of age undergoing local flap reconstruction (bilobe flap, note flap dorsal nasal flap, advancement flap) of a nasal defect following Mohs micrographic surgery. Reconstructive procedures will be performed by Drs. Yang or Patel in the division of Facial Plastic Surgery in the Department of Otolaryngology, Head and Neck Surgery at Vanderbilt University Medical Center.
  • 2. No other facial plastic procedure or sinus surgery performed simultaneously.
  • 3. Lack of all the below exclusion criteria.
  • 1. Known allergy to TXA
  • 2. Intracranial bleeding
  • 3. Known defective color vision
  • 4. History of venous or arterial thromboembolism
  • 5. History of coagulation disorder
  • 6. Active thromboembolic disease
  • 7. Severe renal impairment (diagnosis of chronic kidney disease)
  • 8. History of acute myocardial infarction
  • 9. History of stroke
  • 10. History of seizure
  • 11. History of liver failure
  • 12. Preoperative lab results indicating thrombocytopenia (platelets \<150,000), increased bleeding risk (PT over 45, INR over 1.2).

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Vanderbilt University Medical Center,

Priyesh Patel, MD, PRINCIPAL_INVESTIGATOR, Vanderbilt University Medical Center

Study Record Dates

2024-12